About this episode

Dr. Glenwood Goss joins Dr. Davide Soldato to discuss the implications of adjuvant Durvalumab in early-stage NSCLC and evolving patient care strategies.

Guest Dr. Glenwood Goss and host Dr. Davide Soldato discuss JCO article, " Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer " and the implications of minimal residual disease, results regarding the efficacy of immunotherapy in the adjuvant setting, and the evolving strategies for patient care in lung cancer treatment. LINK TO FULL TRANSCRIPT

More episodes of Journal of Clinical Oncology (JCO) Podcast

• Effectiveness of a Virtual Tobacco Treatment for Cancer Patients · July 16, 2026 · 24 min
• Phase 2 Study of Multi-Cancer Detection from Breath Samples · June 11, 2026 · 20 min
• JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in Melanoma · June 1, 2026 · 10 min
• JCO at ASCO 2026: Pemigatinib Phase 3 FIGHT-302 Trial in Cholangiocarcinoma · June 1, 2026 · 12 min
• JCO at ASCO 2026: Individual Patient Pooled Analysis of Low-Dose Tamoxifen in DCIS · May 31, 2026 · 11 min
• JCO at ASCO 2026: Neoadjuvant Sacituzumab in MIBC · May 31, 2026 · 9 min

Explore listener stats, chart rankings, contacts and more on the Journal of Clinical Oncology (JCO) Podcast podcast page.